Form 8-K - Current report:
SEC Accession No. 0001193125-24-041440
Filing Date
2024-02-21
Accepted
2024-02-21 16:07:08
Documents
14
Period of Report
2024-02-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d699526d8k.htm   iXBRL 8-K 22830
  Complete submission text file 0001193125-24-041440.txt   144410

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ngne-20240215.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngne-20240215_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngne-20240215_pre.xml EX-101.PRE 11255
15 EXTRACTED XBRL INSTANCE DOCUMENT d699526d8k_htm.xml XML 3628
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 24659425
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)